Avni S. Mehta

Avni Mehta practices at NewYork-Presbyterian Westchester in Bronxville, New York.

Avni Mehta's NPI, 1235420035, was assigned on April 27, 2011. Avni Mehta holds New York license 269911.

Avni Mehta's primary practice is NewYork-Presbyterian Westchester, at 55 Palmer Ave, Bronxville, NY 10708. The practice phone is (914) 787-5008.

Avni Mehta's primary practice is NewYork-Presbyterian Westchester in Bronxville, New York. Avni Mehta is also affiliated with NewYork-Presbyterian/Weill Cornell Medical Center. The medical group on file is NewYork-Presbyterian Medical Group Westchester. Dmand AI also links Avni Mehta to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Avni Mehta practices, 3 sites in all. Vendor and product names are available with a free account.

Internal medicine is Avni Mehta's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Avni Mehta is licensed in New York.

CMS data shows 205 Medicare services from Avni Mehta across 4 procedure codes in 2024, for 105 Medicare patients. Medicare paid $18,267 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 105 Medicare patients who saw Avni Mehta in 2024. The largest group is 85 and over, with 38 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 34% are also on Medicaid. Their average risk score is 2.55, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Avni Mehta's median patient age at 84, with 59% women.

In 2024, Avni Mehta wrote 73 Medicare Part D claims for 38 patients. 90% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $29 in total drug cost. In 2019, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 100 out of 100 for Avni Mehta for performance year 2024, reported through an alternative payment model (APM). Avni Mehta accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 3 papers to Avni Mehta, published from 2023 to 2025. The most frequent topics are Cell Line, Tumor and Radiopharmaceuticals. Avni Mehta has published most often in Eur J Nucl Med Mol Imaging.

CMS Open Payments shows 5 general payments to Avni Mehta from 5 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 100% of the total. Allergan Inc. paid the most, $54.